As the final preparations are put in place for the 8th World Stem Cells & Regenerative Medicine Congress, I wanted to highlight some of the must-attend sessions set to take place across the 3 day congress on the 21st-23rd May. Given the expertise and experience of the 2013 speaking faculty, it is a near impossible task to put the spotlight on individual presentations, so make sure you take a look at the full agenda and speaker line up online here.
In no particular order, I wanted to introduce the following 5 presentations occurring in London at the World Stem Cells & Regenerative Medicine Congress:
1. Christopher Calhoun, Chief Executive Officer, Cytori Therapeutics, Inc
In the Cell Therapy & Regenerative Medicine track on Day 1, Christopher Calhoun will be presenting under the heading, Evolving clinical research into multi-centre studies:
- How to improve efficiency of early stage clinical trials
- Importance of supporting translational studies and understanding their value and limitations
- Lessons from early stage clinical development – harnessing promising early results
- Generating robust clinical data with future objectives in mind early on in development
2. Eduardo Bravo, CEO, TiGenix
In the opening plenary session on Day 1, Eduardo Bravo will present to the entire delegation on Commercial financing: exploiting translational funding opportunities:
- Gaining investment – industry's biggest concern
- What sources of funding, resources and support are available developers
- What are the considerations when funding early stage research compared to commercial financing?
3. Sven Kili, Director Global Medical Affairs – Cell Therapy & Regenerative Medicine, Genzyme-a Sanofi Company; Matthias Steger, Global Head Research & Technology Partnering, Hoffman-La Roche; Tim Allsopp, Head of Improve Outreach Programme, Pfizer Regenerative Medicine
In a panel discussion format, the above panellists will be debating on The evolving role of big pharma in the regenerative medicine space:
- Where are large pharma versus specialty pharma looking for in partnering?
- Large pharma's role in crossing the valley of death
- Are we reaching the inflection point for industry investment?
- How to get the attention of a potential partner – gauging levels of interest across the industry
4. Gil Van Bokkelen, President & CEO, Athersys
On the morning plenary session on Day 2 of the congress, Gil Van Bokkelen will be discussing the importance of early dialogue with agencies and operating reimbursement in parallel with accelerated regulatory approval
- What will the payer evidence expectation be for cell therapies?
- How to design your clinical trials with payer expectations in mind: what clinical outcomes will resonate with budget holders?
- Ensure there are reimbursement-relevant endpoints considered in mid-late stage trials
- Emphasising the long term importance of early stage reimbursement modeling
- How to incorporate budget impact models early into development to de-risk failure to reimburse
5. Klaus Kuehlcke, Managing Director, EUFETS GmbH
On the final day of the World Stem Cells & Regenerative Medicine Congress, Klaus Kuehlcke will present on the development of an up-scaled manufacturing process and customized QC assays for a cell therapeutic product
The World Stem Cells & Regenerative Medicine Congress Europe in London on the 21st -23rd May 2013, brings together the late stage cell therapy developers, key opinion leaders, senior regenerative medicine stakeholders and the most innovative stem cell researchers to share expertise and discuss what it takes to achieve successful clinical development and commercialise to scale. Limited places currently remain available, so register before 3rd May 2013 and save Â£100.